ABIOMED Aktie 903092 / US0036541003
256.90
EUR
-12.00
EUR
-4.46%
11:31:16
XQTX
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Historisch | Analysen | |||||
| Ausblick | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.66 |
| Vanguard Group, Inc. (Subfiler) | 11.27 |
| State Street Corp. | 4.59 |
| BlackRock Fund Advisors | 3.69 |
| PRIMECAP Management Co. | 3.34 |
| Wellington Management Co. LLP | 3.22 |
| Vanguard Total Stock Market Index Fund | 3.04 |
| Generation Investment Management LLP | 2.96 |
| Renaissance Technologies LLC | 2.81 |
| Brown Capital Management LLC | 2.80 |
| Winslow Capital Management LLC | 2.78 |
| Vanguard US Growth Fund | 2.70 |
| AllianceBernstein LP | 2.67 |
| Vanguard Mid Cap Index Fund | 2.36 |
| Vanguard 500 Index Fund | 2.31 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1'143 | 1'371 | 1'536 | 1'725 | 2'003 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.52 | 0.56 | 0.55 | 0.49 | 0.52 |
Bilanz (in Mio. EUR) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 494 | 677 | 636 | 788 | 976 |
| Summe Anlagevermögen | 690 | 937 | 1'078 | 1'336 | 1'513 |
| Summe Aktiva | 786 | 1'054 | 1'216 | 1'494 | 1'673 |
Bilanz (in Mio. EUR) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 0 | 0 | 12 | 6 | 10 |
| Summe Fremdkapital | 97 | 117 | 151 | 165 | 170 |
| Summe Eigenkapital | 690 | 937 | 1'065 | 1'330 | 1'503 |
| Summe Passiva | 786 | 1'054 | 1'216 | 1'494 | 1'673 |
Adresse
| 22 Cherry Hill Drive, 01923 Danvers | |
| Telefon | +1 (978) 646-1400 |
| Fax | +1 (978) 777-8411 |
| URL | http://www.abiomed.com |
Management
|
Andrew J. Greenfield
Chief Commercial Officer & Executive VP |
|
Charles A. Simonton
Chief Medical Officer & Executive Vice President |
|
David Fortunati
Director |
|
Jeffrey Blizard
Senior Director-Sales |
|
Karen Mahoney
Chief Human Resources Officer & Vice President |
|
Laxmi N. Peri
Senior Vice President-Engineering |
|
Matt Plano
Executive Vice President-Global Operations |
|
Susan Morano
Director |
|
Thorsten Sieß
Chief Technology Officer & Executive VP |
|
Vincent Sommella
Director |
